Combination Product: EGCG 600 mg + Pirfenidone ( DrugBank: Pirfenidone, EGCG )
1 disease
告示番号 | 疾患名(ページ内リンク) | 臨床試験数 |
---|---|---|
85 | 特発性間質性肺炎 | 1 |
85. 特発性間質性肺炎
臨床試験数 : 627 / 薬物数 : 443 - (DrugBank : 120) / 標的遺伝子数 : 99 - 標的パスウェイ数 : 212
No. | TrialID | Date_ enrollment | Date_ registration | Public_title | Scientific_title | Condition | Intervention | Primary_ sponsor | Secondary_ sponsor | Recruitment_ Status | Inclusion_ agemin | Inclusion_ agemax | Inclusion_ gender | Target_ size | Phase | Countries |
---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
1 | NCT05195918 (ClinicalTrials.gov) | March 1, 2023 | 2/12/2021 | Study of Oral Epigallocatechin-3-gallate (EGCG) in IPF Patients | Dose Ranging Study of Oral Epigallocatechin-3-gallate (EGCG) Given Daily for 12 Weeks to Patients With Idiopathic Pulmonary Fibrosis (IPF) Evaluating Safety, PK Interactions With Standard of Care Drugs, and Biomarkers of Drug Effect | Idiopathic Pulmonary Fibrosis | Combination Product: EGCG 300 mg + Nintedanib;Combination Product: EGCG 300 mg + Pirfenidone;Combination Product: Placebo 2 capsules + Nintedanib or Pirfenidone;Combination Product: EGCG 600 mg + Nintedanib;Combination Product: EGCG 600 mg + Pirfenidone;Combination Product: Placebo 4 capsules + Nintedanib or Pirfenidone | Hal Chapman | University of Michigan;Cornell University;Massachusetts General Hospital;Temple University;University of Washington | Not yet recruiting | 40 Years | 85 Years | All | 50 | Phase 1 | United States |